Carolyn Bertozzi serves as Advisory Board Member at Phylo, an AI-native biomedical research platform that has been adopted by over 7,000 labs across academia and industry. She is the Anne T. and Robert M. Bass Professor at Stanford University and a Howard Hughes Medical Institute Investigator.

Bertozzi earned her B.A. summa cum laude in chemistry from Harvard University in 1988 and her Ph.D. in chemistry from UC Berkeley in 1993. She joined UC Berkeley faculty in 1996 and moved to Stanford in 2015 as Baker Family Director of Sarafan ChEM-H.

Bertozzi was awarded the 2022 Nobel Prize in Chemistry for founding the field of bioorthogonal chemistry, a set of chemical reactions that allow researchers to study molecules in living systems without disrupting natural biological processes. She has co-founded 14 biotechnology companies including Redwood Bioscience (acquired by Catalent in 2014), Palleon Pharmaceuticals, Enable Biosciences, and InterVenn Biosciences.

She is an elected member of the National Academy of Sciences, National Academy of Medicine, and National Academy of Engineering. Her pioneering work has led to breakthrough cancer therapeutics now in clinical trials and rapid tuberculosis diagnostic tests deployed in South Africa.

Bertozzi has mentored over 250 students and postdoctoral fellows and published over 600 scientific papers. She serves on the boards of Alnylam Pharmaceuticals, OmniAb, and Xaira Therapeutics, and her bioorthogonal chemistry methods are now used globally to develop new medicines and diagnostic tools.